Search

Your search keyword '"van Treijen, Mark J.C."' showing total 10 results
Start Over Author "van Treijen, Mark J.C."
10 results on '"van Treijen, Mark J.C."'

1. Head and Neck Paraganglioma (HNPGL) Registry: A study protocol for prospective data collection in patients with Head and Neck Paragangliomas

Author

Zorgeenheid Vaatchirurgie Medisch, Cancer, Genetica Klinische Genetica, MS Endocriene Oncologie, MS Radiologie, MS Radiotherapie, Zorgeenheid KNO Medisch, Brain, MS Hoofd-Hals Chirurgische Oncologie, Circulatory Health, Regenerative Medicine and Stem Cells, MS KNO, de Bresser, Carolijn J.M., van Nesselrooij, Bernadette P.M., van Treijen, Mark J.C., Braat, Arthur J.A.T., de Ridder, Mischa, Stokroos, Robert J., de Bree, Remco, de Borst, Gert J., Rijken, Johannes A., Petri, Bart Jeroen, Zorgeenheid Vaatchirurgie Medisch, Cancer, Genetica Klinische Genetica, MS Endocriene Oncologie, MS Radiologie, MS Radiotherapie, Zorgeenheid KNO Medisch, Brain, MS Hoofd-Hals Chirurgische Oncologie, Circulatory Health, Regenerative Medicine and Stem Cells, MS KNO, de Bresser, Carolijn J.M., van Nesselrooij, Bernadette P.M., van Treijen, Mark J.C., Braat, Arthur J.A.T., de Ridder, Mischa, Stokroos, Robert J., de Bree, Remco, de Borst, Gert J., Rijken, Johannes A., and Petri, Bart Jeroen

Published
2024

2. The Additional Value of Somatostatin Receptor Positron Emission Computed Tomography ([68Ga]Ga-DOTATOC PET/CT) Compared with Magnetic Resonance Imaging of the Head and Neck Region in Paraganglioma Patients: A Pilot Study

Author

Zorgeenheid Vaatchirurgie Medisch, Circulatory Health, MS Radiologie, Cancer, MS Endocriene Oncologie, Brain, MS Radiotherapie, MS Hoofd-Hals Chirurgische Oncologie, Regenerative Medicine and Stem Cells, MS KNO, de Bresser, Carolijn J.M., Petri, Bart Jeroen, Braat, Arthur J.A.T., de Keizer, Bart, van Treijen, Mark J.C., Dankbaar, Jan Willem, Pameijer, Frank A., Kok, Marius G.J., de Ridder, Mischa, van Nesselrooij, Bernadette P.M., de Bree, Remco, de Borst, Gert J., Rijken, Johannes A., Zorgeenheid Vaatchirurgie Medisch, Circulatory Health, MS Radiologie, Cancer, MS Endocriene Oncologie, Brain, MS Radiotherapie, MS Hoofd-Hals Chirurgische Oncologie, Regenerative Medicine and Stem Cells, MS KNO, de Bresser, Carolijn J.M., Petri, Bart Jeroen, Braat, Arthur J.A.T., de Keizer, Bart, van Treijen, Mark J.C., Dankbaar, Jan Willem, Pameijer, Frank A., Kok, Marius G.J., de Ridder, Mischa, van Nesselrooij, Bernadette P.M., de Bree, Remco, de Borst, Gert J., and Rijken, Johannes A.

Published
2024

4. NETest: serial liquid biopsies in gastroenteropancreatic NET surveillance

Author

MS Endocriene Oncologie, Cancer, van Treijen, Mark J.C., Korse, Catharina M., Verbeek, Wieke H., Tesselaar, Margot E.T., Valk, Gerlof D., MS Endocriene Oncologie, Cancer, van Treijen, Mark J.C., Korse, Catharina M., Verbeek, Wieke H., Tesselaar, Margot E.T., and Valk, Gerlof D.

Published
2022

5. FDG PET/CT in differentiated thyroid cancer patients with low thyroglobulin levels

Author

Endocrinologie onderzoek, CTC, Cancer, MS CGO, Regenerative Medicine and Stem Cells, MS Radiologie, MS Endocriene Oncologie, Heelkunde Opleiding, Endocrinologie patientenzorg, Brain, Child Health, Lebbink, Chantal A., de Vries, Lisa H., Borel Rinkes, Inne H.M., Braat, Arthur J.A.T., van Leeuwaarde, Rachel S., Lodewijk, Lutske, van Treijen, Mark J.C., Vriens, Menno R., Valk, Gerlof D., van Santen, Hanneke M., de Keizer, Bart, Endocrinologie onderzoek, CTC, Cancer, MS CGO, Regenerative Medicine and Stem Cells, MS Radiologie, MS Endocriene Oncologie, Heelkunde Opleiding, Endocrinologie patientenzorg, Brain, Child Health, Lebbink, Chantal A., de Vries, Lisa H., Borel Rinkes, Inne H.M., Braat, Arthur J.A.T., van Leeuwaarde, Rachel S., Lodewijk, Lutske, van Treijen, Mark J.C., Vriens, Menno R., Valk, Gerlof D., van Santen, Hanneke M., and de Keizer, Bart

Published
2022

6. Metastatic patterns of duodenopancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1

Author

Pathologie Groep Brosens, Cancer, MS CGO, Pathologie, MS Endocriene Oncologie, Regenerative Medicine and Stem Cells, Pathologie Pathologen staf, Heelkunde Opleiding, Hackeng, Wenzel M., van Beek, Dirk Jan, Kok, Aranxa S.M., van Emst, Madelon, Morsink, Folkert H.M., van Treijen, Mark J.C., Borel Rinkes, Inne H.M., Dreijerink, Koen M.A., Offerhaus, G. Johan A., Valk, Gerlof D., Vriens, Menno R., Brosens, Lodewijk A.A., Pathologie Groep Brosens, Cancer, MS CGO, Pathologie, MS Endocriene Oncologie, Regenerative Medicine and Stem Cells, Pathologie Pathologen staf, Heelkunde Opleiding, Hackeng, Wenzel M., van Beek, Dirk Jan, Kok, Aranxa S.M., van Emst, Madelon, Morsink, Folkert H.M., van Treijen, Mark J.C., Borel Rinkes, Inne H.M., Dreijerink, Koen M.A., Offerhaus, G. Johan A., Valk, Gerlof D., Vriens, Menno R., and Brosens, Lodewijk A.A.

Published
2022

7. Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1

Author

Hackeng, Wenzel M., primary, van Beek, Dirk-Jan, additional, Kok, Aranxa S.M., additional, van Emst, Madelon, additional, Morsink, Folkert H.M., additional, van Treijen, Mark J.C., additional, Borel Rinkes, Inne H.M., additional, Dreijerink, Koen M.A., additional, Offerhaus, G. Johan A., additional, Valk, Gerlof D., additional, Vriens, Menno R., additional, and Brosens, Lodewijk A.A., additional

Published
2021
Full Text
View/download PDF

8. Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients:Results from the DutchMEN Study Group

Author

Klein Haneveld, Mirthe J., Van Treijen, Mark J.C., Pieterman, Carolina R.C., Dekkers, Olaf M., Van De Ven, Annenienke, De Herder, Wouter W., Zandee, Wouter T., Drent, Madeleine L., Bisschop, Peter H., Havekes, Bas, Vriens, Menno R., Verrijn Stuart, Annemarie A., Valk, Gerlof D., Van Leeuwaarde, Rachel S., Klein Haneveld, Mirthe J., Van Treijen, Mark J.C., Pieterman, Carolina R.C., Dekkers, Olaf M., Van De Ven, Annenienke, De Herder, Wouter W., Zandee, Wouter T., Drent, Madeleine L., Bisschop, Peter H., Havekes, Bas, Vriens, Menno R., Verrijn Stuart, Annemarie A., Valk, Gerlof D., and Van Leeuwaarde, Rachel S.

Abstract

Context: Nonfunctioning pancreatic neuroendocrine tumors (NF-pNETs) are highly prevalent and constitute an important cause of mortality in patients with multiple endocrine neoplasia type 1 (MEN1). Still, the optimal age to initiate screening for pNETs is under debate. Objective: The aim of this work is to assess the age of occurrence of clinically relevant NF-pNETs in young MEN1 patients. Methods: Pancreatic imaging data of MEN1 patients were retrieved from the DutchMEN Study Group database. Interval-censored survival methods were used to describe age-related penetrance, compare survival curves, and develop a parametric model for estimating the risk of having clinically relevant NF-pNET at various ages. The primary objective was to assess age at occurrence of clinically relevant NF-pNET (size ≥†20 mm or rapid growth); secondary objectives were the age at occurrence of NF-pNET of any size and pNET-associated metastasized disease. Results: Five of 350 patients developed clinically relevant NF-pNETs before age 18 years, 2 of whom subsequently developed lymph node metastases. No differences in clinically relevant NF-pNET-free survival were found for sex, time frame, and type of MEN1 diagnosis or genotype. The estimated ages (median, 95% CI) at a 1%, 2.5%, and 5% risk of having developed a clinically relevant tumor are 9.5 (6.5-12.7), 13.5 (10.2-16.9), and 17.8 years (14.3-21.4), respectively. Conclusion: Analyses from this population-based cohort indicate that start of surveillance for NF-pNETs with pancreatic imaging at age 13 to 14 years is justified. The psychological and medical burden of screening at a young age should be considered.

Published
2021

9. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®

Author

van Treijen, Mark J.C., primary, van der Zee, Dennis, additional, Heeres, Birthe C., additional, Staal, Femke C.R., additional, Vriens, Menno R., additional, Saveur, Lisette J., additional, Verbeek, Wieke H.M., additional, Korse, Catharina M., additional, Maas, Monique, additional, Valk, Gerlof D., additional, and Tesselaar, Margot E.T., additional

Published
2020
Full Text
View/download PDF

10. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.

Author

van Treijen, Mark J.C., van der Zee, Dennis, Heeres, Birthe C., Staal, Femke C.R., Vriens, Menno R., Saveur, Lisette J., Verbeek, Wieke H.M., Korse, Catharina M., Maas, Monique, Valk, Gerlof D., and Tesselaar, Margot E.T.

Subjects
*GENOMICS, *NEUROENDOCRINE tumors, *DISEASE progression, *RECEIVER operating characteristic curves, *WATCHFUL waiting
Abstract

Reliable prediction of disease status is a major challenge in managing gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The aim of the study was to validate the NETest®, a blood molecular genomic analysis, for predicting the course of disease in individual patients compared to chromogranin A (CgA). NETest® score (normal ≤20%) and CgA level (normal <100 µg/L) were measured in 152 GEP-NETs. The median follow-up was 36 (4–56) months. Progression-free survival was blindly assessed (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1). Optimal cutoffs (area under the receiver operating characteristic curve [AUC]), odds ratios, as well as negative and positive predictive values (NPVs/PPVs) were calculated for predicting stable disease (SD) and progressive disease (PD). Of the 152 GEP-NETs, 86% were NETest®-positive and 52% CgA-positive. -NETest® AUC was 0.78 versus CgA 0.73 (p = ns). The optimal cutoffs for predicting SD/PD were 33% for the NETest® and 140 µg/L for CgA. Multivariate analyses identified NETest® as the strongest predictor for PD (odds ratio: 5.7 [score: 34–79%]; 12.6 [score: ≥80%]) compared to CgA (odds ratio: 3.0), tumor grade (odds ratio: 3.1), or liver metastasis (odds ratio: 7.7). The NETest® NPV for SD was 87% at 12 months. The PPV for PD was 47 and 64% (scores 34–79% and ≥80%, respectively). NETest® metrics were comparable in the watchful waiting, treatment, and no evidence of disease (NED) subgroups. For CgA (>140 ng/mL), NPV and PPV were 83 and 52%. CgA could not predict PD in the watchful waiting or NED subgroups. The NETest® reliably predicted SD and was the strongest predictor of PD. CgA had lower utility. The -NETest® anticipates RECIST-defined disease status up to 1 year before imaging alterations are apparent. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results